Imagen de Portada

Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection—Questions Focused on Clinical Practice

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Javier P. Gisbert, Pablo Parra, Olga P. Nyssen
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
por: Olga P. Nyssen, et al.
Publicado: (2025)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
por: María Chaparro, et al.
Publicado: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?
por: Fernanda Cristofori, et al.
Publicado: (2025)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
por: Irene Spinelli, et al.
Publicado: (2025)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
por: María José García, et al.
Publicado: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
por: María José García, et al.
Publicado: (2024)

Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
por: Sydney Pomenti, et al.
Publicado: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
por: Cristina Rubín de Célix, et al.
Publicado: (2025)

Review Article: Drug Approval for Gastroparesis—Suggestions for Improving the Process for Positive Results
por: Michael Camilleri, et al.
Publicado: (2026)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
por: Jannis Kountouras, et al.
Publicado: (2024)

Letter: Meta‐Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis
por: Haleema Rahman
Publicado: (2025)

Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation
por: Erin R. Bonner, et al.
Publicado: (2025)

Review Article: Drug‐Induced Liver Injury Associated With Antibody‐Based Therapies in Haematologic Malignancies
por: Mengmeng Lin, et al.
Publicado: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
por: Manjeet Kumar Goyal, et al.
Publicado: (2026)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH
por: Jannis Kountouras, et al.
Publicado: (2024)

Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis
por: Enzo Emanuele, et al.
Publicado: (2025)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
por: S. K. Bansal, et al.
Publicado: (2024)

Letter: Disappearing Microbe, Emerging Disease? Nuancing the Protective Effects of Helicobacter pylori Against Eosinophilic Oesophagitis. Authors' Reply
por: Irene Spinelli, et al.
Publicado: (2025)

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
por: Jannis Kountouras, et al.
Publicado: (2025)

Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion
por: Cathy Lu, et al.
Publicado: (2025)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis
por: Jörn M. Schattenberg, et al.
Publicado: (2026)

Editorial for ‘Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance, and Expansion’
por: Cameron Kendall, et al.
Publicado: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
por: Giovanni Cammarota, et al.
Publicado: (2024)

Letter: Helicobacter pylori and metabolic syndrome‐related von Willebrand factor and plasminogen activator inhibitor‐1 activity levels for outcome prediction of advanced chronic liver disease
por: Jannis Kountouras, et al.
Publicado: (2024)

Review Article: Individualised Management of Reflux‐Like Symptoms—Strategies Beyond Acid Suppression
por: Peter J. Kahrilas, et al.
Publicado: (2025)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach
por: Riccardo Vasapolli, et al.
Publicado: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
por: Olga M. Nardone, et al.
Publicado: (2025)

Review Article: Surrogate Endpoints to Assess Treatment Efficacy in Disorders of Gut–Brain Interaction of Lower Gastrointestinal Tract
por: Michael Camilleri, et al.
Publicado: (2025)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
por: Shuaibing Ying, et al.
Publicado: (2026)

Editorial: H. pylori Antimicrobial Susceptibility Testing—An Expanding Toolbox
por: Suvithan Rajadurai, et al.
Publicado: (2024)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
por: Maryam Zafer, et al.
Publicado: (2025)

Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply
por: Nikolaj Torp, et al.
Publicado: (2025)

Impact of Clinical and Pharmacological Parameters on Faecal Microbiota Transplantation Outcome in Clostridioides difficile Infections: Results of a 5‐Year French National Survey
por: Nicolas Benech, et al.
Publicado: (2024)

Review article: Oesophageal disorders in chronic liver disease
por: Francisco Idalsoaga, et al.
Publicado: (2024)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
por: Supachaya Sriphoosanaphan, et al.
Publicado: (2025)

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study
por: Sara Ellegaard Paaske, et al.
Publicado: (2025)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
por: Bernardo de Faria Moraes, et al.
Publicado: (2026)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
por: Paul Y. Kwo, et al.
Publicado: (2026)

Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids
por: Abdel‐Aziz Shaheen, et al.
Publicado: (2026)